Michael A. Dyer, Ph.D., a Career Development awardee at the University of Tennessee Health Science Center, has developed novel therapeutic approaches for treating retinoblastoma, a debilitating childhood eye cancer.

Ocular Cancer

Some ocular (eye) cancers are primary cancers, meaning they start in the eye.  Others are secondary cancers, having spread (metastasized) to the eye from another location.  Approximately 2,200 new cases of ocular cancers occur in the U.S. each year.  Most are in people over 50, but children can also be affected.

The most common primary eye cancer in adults is uveal melanoma in which tumors arise from melanocytes (cells that give color to the eye).  The melanocytes become cancerous along the uvea, the middle layer of the eyeball that includes structures called the iris, ciliary body, and choroid.  Researchers are aggressively investigating ways to prevent the spread of uveal melanoma to other parts of the body.

Retinoblastoma (cancer of the retina) is the most common eye tumor in children, usually occurring before the age of two and almost always before age five.  About 350 new cases of retinoblastoma are diagnosed in the U.S. each year.  The cancer is caused by a gene mutation that disrupts the production of a certain protein by cells of the retina.  In approximately 10 percent of cases, the gene mutation is inherited from a parent.  The tumor can arise in one eye or both.